Looking to build a 'dual sourcing' supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant

Biologics have been particularly hot in 2020 with big drugmakers looking to bolster their portfolio — a trend that has been a serious boon for contract manufacturers. WuXi Biologics started off the year adding to its own production capacity in Germany to keep up with that expected demand, and now it’s going back to Deutschland for another expansion.